RT Journal Article SR Electronic T1 Endobronchial valve therapy for patients with advanced emphysema. A report from a tertiary care center in China JF Saudi Medical Journal JO Saudi Med J FD Prince Sultan Military Medical City SP 1397 OP 1401 DO 10.15537/smj.2022.43.12.20220527 VO 43 IS 12 A1 Hang Yu A1 Zhen Yang A1 Minghui Zhu A1 Zhixin Liang A1 Wei Zhao A1 Qiang Zhu A1 Liang-an Chen YR 2022 UL http://smj.org.sa/content/43/12/1397.abstract AB Objectives: To assess the efficiency and safety of endobronchial valve (EBV) treatment in Chinese patients.Methods: A retrospective analysis was performed in patients with chronic obstructive pulmonary disease who underwent EBV implantation in our hospital between October 2010 and January 2017. All patients were confirmed with no collateral ventilation (CV-) or with low airflow (LF) in the treated lobe. Pulmonary function parameters, the 6-minute walk distance (6MWD), the modified Medical Research Council (mMRC), as well as adverse events in the follow-up period were recorded.Results: Thirty-eight advanced emphysema patients received EBV implantation. Significant improvements were found in forced expiratory volume in 1 second (FEV1)(FEV1: +0.12 L), 6MWD (+64.9 m), and mMRC (-0.5 points). A total of 55.3% and 65.8% of subjects met the score for the minimal clinically important difference in FEV1 and 6MWD, respectively. FEV1 improved more significantly in the CV- group than in the LF group. Pneumothorax or death did not occur during the follow-up period.Conclusion: Endobronchial valve treatment in patients with advanced emphysema and CV- provides clinically meaningful benefits with a low incidence of pneumothorax. The efficiency and safety of EBV therapy are acceptable in China.